Business Acquisition (Details Narrative) |
3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
|
Oct. 23, 2020
USD ($)
ft²
|
Jun. 30, 2021
USD ($)
ft²
|
Jun. 30, 2021
USD ($)
ft²
|
Dec. 31, 2020
USD ($)
|
|
| Business Acquisition [Line Items] | ||||
| Goodwill | $ 901,000 | $ 901,000 | $ 901,000 | $ 901,000 |
| Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets | 1,599,000 | |||
| Amortization | $ 109,000 | $ 207,000 | ||
| Consulting Agreement [Member] | Mr. Gurnani [Member] | ||||
| Business Acquisition [Line Items] | ||||
| Aggregate cost consideration | 300,000 | |||
| CLIA License [Member] | ||||
| Business Acquisition [Line Items] | ||||
| Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets | 1,300,000 | |||
| Plaza Medical Laboratory Corp [Member] | ||||
| Business Acquisition [Line Items] | ||||
| Business Combination, Consideration Transferred | $ 2,500,000 | |||
| Area of Land | ft² | 4,000 | 4,000 | 4,000 |
| X | ||||||||||
- Definition Aggregate cost consideration. No definition available.
|
| X | ||||||||||
- Definition The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Area of land held. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of assets acquired at the acquisition date. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|